Remlarsen treatment increased corneal re-epithelialization, decreased corneal scar formation, and repressed the expression of several pro-fibrotic genes when compared to placebo treated eyes in a prec...
Cobomarsen expansion indication data released; first observations from the ongoing Phase 1 clinical trial on safety and efficacy of cobomarsen in ATLL patients, additional data expected by year endNew...
BOULDER, Colo. and RYE BROOK, N.Y., Aug. 06, 2018 (GLOBE NEWSWIRE) -- miRagen Therapeutics, Inc. (NASDAQ: MGEN), a clinical-stage biopharmaceutical company focused on the discovery and development o...
BOULDER, Colo., July 31, 2018 (GLOBE NEWSWIRE) -- miRagen Therapeutics, Inc. (NASDAQ:MGEN), a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therap...
BOULDER, Colo., July 25, 2018 (GLOBE NEWSWIRE) -- miRagen Therapeutics, Inc. (NASDAQ:MGEN), a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therap...
